No. Makes more sense to license the asset (molecule). And even then, big pharma companies won’t talk to you until your molecule is in phase 2.

If anybody with an AI pharma start up tells you they plan to make money by licensing their platform, then run the other way because it is a red flag.

If you want to see what a real “AI” pharma company looks like check out Vertex pharmaceuticals.